December 20, 2024

Several key trends in the pharmacy benefits landscape significantly impacted plan sponsors and employers in 2024. Despite their cost-saving potential, the delayed adoption of biosimilars highlighted the influence of formulary placements and misaligned incentives within the pharmacy benefit managers (PBM) space. Employers also faced growing scrutiny over their fiduciary responsibilities, particularly as lawsuits highlighted the rising costs of generic specialty medications. The Inflation Reduction Act (IRA) introduced new pricing provisions, and while PBM-related legislation essentially stalled at the federal level, states made notable progress on transparency and pricing reforms. Additionally, the rising use and costs of GLP-1 medications and ongoing supply shortages created challenges in managing benefits. Below are quick summaries of these trends, with additional information that provides further insights into their implications for employers navigating this complex environment.

Biosimilars 

While adalimumab products, biosimilar agents to Humira used for multiple inflammatory conditions, launched in 2023, the delayed rise of their market share was a top story of 2024. Multiple factors played a role in the continued dominance of the brand-name product when a more cost-effective alternative biosimilar was available. However, formulary placement at PBMs was the most significant factor. When formulary placements finally favored biosimilars, another misaligned incentive arose with the Big Three PBMs utilizing products from private labeling companies owned by the same parent companies. 

Fiduciary Responsibility:

Before 2024, self-funded plan sponsors already had a fiduciary responsibility to provide affordable access to health care for plan members as part of their self-insured plan designs. However, this responsibility gained heightened attention due to lawsuits filed this year, which highlighted the risks employers face regarding pharmacy benefits. Notably, companies like Johnson & Johnson and Wells Fargo were at the center of these legal challenges. Employees filed suits alleging that generic specialty medications were being priced much higher under their Pharmacy Benefit Manager (PBM) plans compared to other sources.

Inflation Reduction Act (IRA)

The IRA initiated multiple changes in recent years, with some adjustments starting, or being announced, in 2024. Brand pricing of insulins and inhalers  was lowered in part due to the IRA’s Average Manufacture Price Cap (AMP Cap) provision. Also, in 2024, the price of popular brand-name medications available on Medicare as CMS could be negotiated for the first time. The impact of CMS drug pricing negotiations for employer-sponsored health plans remains to be seen.  

Federal Trade Commission (FTC) Interim PBM Report

In July of 2024, the FTC released a 73-page report on its assessment of the role that PBMs play as middlemen. Very little in the report was news to those who work in the pharmacy benefit space, but the report brought new reporting and attention to the topic. While PBMs disagree with the findings, the information included continues to point to the misaligned incentives currently at the center of PBM concerns.  

PBM Legislation

While often reported, federal legislative attempts surrounding PBMs mainly fell flat in 2024. States, however, did have more success with various combinations of laws passed related to transparency, pass-through pricing, any willing provider pharmacy and point-of-sale rebates. It is yet to be determined how state regulations will directly impact ERISA plans. 

GLP-1 Medications

If a plan sponsor received a list of the top drugs and/or fastest-rising drugs for 2024, chances are multiple GLP-1 or GLP-1/GIP medications were on that list. The utilization and price impact of GLP-1s for diabetes in and of themselves is enough to make this a top story, but so much more is involved. 

  • GLP-1 and GLP-1/GIP for weight management: Plan sponsors continue to assess if they can afford to cover these high-cost agents for obesity management, while those that did in 2024 often found themselves in the news after removing coverage when the cost became unsustainable. 
  • GLP-1 expanding indications: Based on released data, 2024 brought an expansion for secondary cardiovascular prevention and still has the potential to bring an indication for sleep apnea. With each additional indication comes additional utilization and spend. 
  • GLP-1 shortages and the rise of compounding: Manufacturers found themselves unable to keep up with the demand for GLP-1 and GLP-1/GIP medications. This led to these drugs being placed on the FDA shortage list and opened opportunities for others to compound them. Compounding often came with a lower price, but an increased risk to patients. 

Disaggregation of the PBM System

Three PBMs have 80% of the market share. While mid-market transparent PBMs are picking up new employers every year, the trend of these three traditional PBMs controlling most of the market continued. In 2024, large corporations announced they were replacing the mainstream PBMs, and interest and excitement over deregulating the PBM system grew. From changing pharmacy networks, such as adding cost-plus pharmacy models, to carving out specialty PBMs, like many of our clients utilize today, the year brought forth innovation and a focus on moving past the status quo. 

Looking forward to 2025, we invite you to join us in monitoring how these trends continue to evolve or shift. Regulatory changes, emerging medications and innovative employer-driven solutions shape the future of pharmacy benefits. Employers, especially those in Total Rewards roles, must stay informed and agile in adapting their strategies as the landscape transforms. Together, we can explore future opportunities and challenges in managing pharmacy spend while optimizing employee and organization benefits. Check out our website for all the latest industry updates. 

 

I want to talk to a pharmacist.